AI Article Synopsis
- Lp(a) is recognized as a key risk factor for atherosclerotic cardiovascular diseases, affecting about 20% of people.
- Evidence indicates a direct link between high Lp(a) levels and increased risks of heart issues, like heart attacks and strokes, as well as conditions like aortic stenosis.
- The statement discusses recommendations for testing Lp(a) in clinical settings and how to use Lp(a) levels to guide treatment strategies in both preventing and managing cardiovascular diseases.
Article Abstract
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease-related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacl.2019.04.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!